Newsletter | Edition N.1 | 2014
View this email in your browser

Glythera is a biotechnology company specializing in the development of next generation therapeutics through the application of its linker and stable glycan technologies PermaLink™ and PermaCarb™.

These technologies offer
improved stability, bioavailability and efficiency in oncology and therapeutics applications. 

We are open to opportunities for technology out-licensing, collaboration or provision of full service business models for the use of PermaLink™ or PermaCarb™.

If you are looking to improve control, efficiency and post-transitional modification in the development of protein conjugates and biotherapeutics then our dedicated team would be happy to discuss the opportunities with you. 

Herschel Annex, King's Road, Newcastle-upon-Tyne
NE1 7RU, UK.
  +44 (0) 191 2223836
  Follow us!
Welcome to our latest newsletter, designed to provide you with updates from Glythera and let you know where you can meet us at upcoming industry events 

Glythera News

Glythera Knowledge Transfer

Glythera Upcoming Events
Glythera Technical Director Jenny Thirlway will attend the Annual Proteins and Antibodies Congress on 3rd & 4th April 2014 at the Novotel London West, UK. 
Glythera Technical Director Jenny Thirlway will attend the Antibody Drug Conjugates Congress on 18 & 19 June 2014 at the Crowne Plaza Barcelona Fira Center, Spain.
Copyright © *2014* *Glythera*, All rights reserved.
Please consider the environment before printing this Newsletter

Our mailing address is:
Glythera · Herschel Annex, King's Road · Newcastle Upon Tyne, Tyne and Wear NE1 7RU · United Kingdom

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp